# OnCo record prostate-mcrpc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/prostate-mcrpc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "prostate-mcrpc" ;
  schema:name "Metastatic castration-resistant prostate cancer"@en ;
  schema:alternateName "mCRPC"@en, "Metastatic CRPC"@en, "Castration-resistant metastatic prostate cancer"@en, "Hormone-refractory prostate cancer (older term)"@en ;
  schema:description "Metastatic castration-resistant prostate cancer is disease that grows despite castrate testosterone. Sequenced treatments now include androgen receptor inhibitors, docetaxel and cabazitaxel, PARP inhibitors for men with BRCA-type mutations, the radioligand 177Lu-PSMA-617 and radium-223 for bone-predominant disease."@en ;
  schema:url <https://onco.cc/cancers/prostate-mcrpc/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer>, <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/drugs/lu177-psma-it/>, <https://onco.cc/drugs/pasritamig/>, <https://onco.cc/drugs/opevesostat/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/bms-986365/>, <https://onco.cc/drugs/fpi-2265/>, <https://onco.cc/drugs/ifinatamab-deruxtecan/>, <https://onco.cc/drugs/hs-20093/> ;
  onco:standardOfCare <https://onco.cc/drugs/abiraterone/>, <https://onco.cc/drugs/enzalutamide/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/propel/>, <https://onco.cc/trials/talapro-2/>, <https://onco.cc/trials/magnitude/>, <https://onco.cc/drugs/docetaxel/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/trials/profound/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/trials/psmafore/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/pluvicto/>, <https://onco.cc/trials/vision/>, <https://onco.cc/drugs/cabazitaxel/>, <https://onco.cc/drugs/radium-223/>, <https://onco.cc/trials/alsympca/>, <https://onco.cc/trials/therap/>, <https://onco.cc/drugs/denosumab/>, <https://onco.cc/drugs/zoledronic-acid/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/drugs/ac225-psma/>, <https://onco.cc/drugs/xaluritamig/>, <https://onco.cc/drugs/mevrometostat/>, <https://onco.cc/drugs/lu177-psma-it/>, <https://onco.cc/trials/alphabreak/>, <https://onco.cc/trials/xalute/>, <https://onco.cc/trials/mevpro-1/>, <https://onco.cc/trials/splash/>, <https://onco.cc/trials/eclipse-psma/> .